Sign up online today & collaborate
or click here to find out more
CureVac, a pioneer in the field of mRNA-based technology, today announced that the company has initiated its third target product development program in collaboration with the Bill & Melinda Gates Foundation.
The program will leverage CureVac’s RNActive technology platform in the development of a prophylactic vaccine to protect against respiratory syncytial virus (RSV), adding to the development programs previously initiated by CureVac and the Gates Foundation targeting mRNA vaccines for HIV and Rotavirus.
For more click here